Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of CLS001 for Corneal Endothelial Cell Regenerative Therapy | DNA RNA and Cells

Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of CLS001 for Corneal Endothelial Cell Regenerative Therapy

Related Keywords

Toho ,Saga ,Japan ,Tokyo ,Japanese , ,Toho Holding ,Ministry Of Health ,Health Sciences Council ,Toyo Seikan Group Holdings ,Keio Innovation Initiative ,Keio University ,Icellusion Inc ,Keio University Hospital ,Toho Holdings ,University Of Tokyo Edge Capital Partners ,Cellusion Raises ,Advance Japan ,Global Clinical Trials ,Corneal Endothelial Cell Regenerative Therapy ,Japani January ,Corneal Endothelial Cell Substitute ,Tokyo Edge Capital ,Bullous Keratopathy ,Corneal Endothelial ,Keio University Specially Certified Committee ,Regenerative Medicine ,Biologics ,Na ,Gene Therapy ,Dirna ,Unai ,Antisense ,Oligonucleotides ,Cells ,Cell Therapy ,Stem Cells ,